(MENAFN- IANS) 
New Delhi, June 24 (IANS) Ramdevs Patanjali Research Institute (PRI), which has developed Coronil that has been claimed as a cure for Covid-19, has discovered that natural phytochemicals in ashwagandha, giloy and tulsi have the potential to combat Covid-19 and its pathogenicity.
The prescribed intervention includes ashwagandha, giloy, tulsi, anu taila and swasari ras. The research and trials were conducted at the NIMS University in Jaipur.
The Covid-19 infection is known to affect individuals with weak immunity more severely. "Therefore, enhancing immunity is definitely one of the ways the doctors across the globe have been using for treating Covid 19 cases," according to a Patanjali report.
According to the report, to combat Covid-19 with Ayurveda, "we have screened close to 1,000 phytochemicals from more than 100 medicinal plants. We looked for their binding affinities to Covid-19 essential proteins and host protein interactions."
"We have discovered that natural phytochemcials in ashwagandha, giloy and tulsi have the potential to combat Covid-19 and its pathogenicity," Patanjali said.
In reply to a questionnaire from the Ministry of Ayush, the Patanjali Research Institute, Haridwar, pointed out that the clinical trials for the Ayurvedic medicines were conducted and registered with the Clinical Trial Registry of India (CTRI) as per the guidelines of the Clinical Evaluation of Ayurvedic Interventions by the Central Council for Research in Ayurvedic Sciences, Ministry of Ayush.
The Patanjali reply signed by Acharya Balkrishna said the clinical trials were also communicated to the Director General of the Council in an email by the Principal Investigator, Ganpat Devpura.
--IANS
san/arm
MENAFN2406202002310000ID1100378665
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.